Tumor Metformin Research Articles

Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer

SummaryLate-phase clinical trials investigating metformin as a cancer therapy are underway. However, there remains controversy as to the mode of action of metformin in tumors at clinical doses. We conducted a clinical study integrating measurement of markers of systemic metabolism, dynamic FDG-PET-CT, transcriptomics, and metabolomics at paired time points to profile the bioactivity of metformin in primary breast cancer. We show metformin reduces the levels of mitochondrial metabolites, activates multiple mitochondrial metabolic pathways, and increases 18-FDG flux in tumors. Two tumor groups are identified with distinct metabolic responses, an OXPHOS transcriptional response (OTR) group for which there is an increase in OXPHOS gene transcription and an FDG response group with increased 18-FDG uptake. Increase in proliferation, as measured by a validated proliferation signature, suggested that patients in the OTR group were resistant to metformin treatment. We conclude that mitochondrial response to metformin in primary breast cancer may define anti-tumor effect.

Abstract PR15: Antitumor effect of metformin in breast cancer is associated with AMPK and FOXO3a activation

Abstract Epidemiological studies have associated obesity with a wide variety of cancers such as metastatic breast cancer. Insulin resistance and hyperinsulinemia have been proposed as the mechanisms by which obesity induces or promotes tumorigenesis. Metformin, an anti-diabetic drug commonly prescribed to treat type 2 diabetes, has recently received attention as a potentially useful therapeutic agent for reducing cancer risk. It is reported to not only have a direct antitumoral effect, but also to act indirectly to improve insulin sensitivity, decreases hyperinsulinemia, and consequently attenuate tumor proliferation. The objective of the present study was to examine the influence of obesity in an experimental breast tumor model and to analyze the effect of metformin on it. Obesity was induced in newborn male Wistar rats by subcutaneous injection of 400mg/kg body weight monosodium glutamate (MSG) (obese) or saline (control) at 2, 3, 4, 5 and 6 days of age. After 16 weeks, 1x107 Walker-256 tumor cells, a rat breast carcinosarcoma cell lines, were subcutaneously injected in the right flank of the rats and concomitantly were treated with metformin (300mg/kg body weight, via gavage, for 15 days). Following this treatment, the rats were divided into 4 groups: control tumor (CT), control tumor metformin (CTM), obese tumor (OT) and obese tumor metformin (OTM). The effect of metformin on tumor development was assessed at the 18th week. Tumor development was higher in OT rats compared with CT rats which correlated with reduced life span in OT compared with CT rats. Metformin reduced the tumor development in OT rats and prolonged the life span of the rats. Metformin increased the mRNA expression of cell cycle regulators pRb and p27. Furthermore, metformin increased AMPK and FOXO3a activities, and decreased p-p38 and p-ERK1/2 expression in CTM and OTM groups. In order to further explore the molecular mechanism of the antiproliferative role of metformin, breast cancer MCF-7 cells were treated with metformin for 24, 48 and 72 hours. Results indicated that the antiproliferative effect of metformin was both time- and dose-dependent. This effect was associated with an increase in oxidative stress, apoptosis, necrosis and cell cycle arrest in G0-G1 phase as measured by flow cytometry. Metformin also increased mRNA expression of FOXO3a, p27, Bax and decreased the mRNA expression of cyclin D1 and Bcl-2 as well as decreased the Bcl-2 protein expression. Furthermore, metformin increased AMPK and FOXO3a activities. Moreover, the combination of metformin+2-deoxyglucose, an inhibitor of glycolysis, as well as metformin+H2O2 exhibited an even stronger antiproliferative effect as compared to the individual treatments. In conclusion, we have demonstrated that obesity has an important role in tumor development, increasing the tumor size and reducing the life span of the rats. We have also demonstrated that metformin was effective in controlling tumor development and prolonging the survival; effects associated with AMPK and FOXO3a. Financial support: FAPESP and CNPq (Brazil), NSERC-RCD and NOSM (Canada). This abstract is also presented as Poster A97. Citation Format: Eveline A. I. Fonseca, Maria Aparecida Oliveira, Rosangela Eichler, Eliana H. Akamine, Maria Helena C. Carvalho, Aneli M. Barbosa, Robert F. H. Dekker, Neelam Khaper, Zuleica B. Fortes. Antitumor effect of metformin in breast cancer is associated with AMPK and FOXO3a activation. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Invasion and Metastasis; Jan 20-23, 2013; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2013;73(3 Suppl):Abstract nr PR15.